Form 8-K

8-K — Glucotrack, Inc.

Accession: 0001493152-26-013654

Filed: 2026-03-30

Period: 2026-03-30

CIK: 0001506983

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001506983

2026-03-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 30, 2026

GLUCOTRACK,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-41141

98-0668934

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

301

Rte 17 North, Ste. 800, Rutherford, NJ

07070

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (201) 842-7715

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

GCTK

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §

230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

March 30, 2026, Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results

for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The

information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities

Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated March 30, 2026

104

Cover

Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

March 30, 2026

GLUCOTRACK,

INC.

By:

/s/

Paul Goode

Name:

Paul

Goode

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Glucotrack

Reports Fourth Quarter and Full Year 2025

Financial

Results and Recent Corporate Highlights

Company

prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half

of 2026

Patent and Trademark Office (USPTO) issued patents for Glucotrack’s implantable

continuous

blood glucose monitoring (CBGM) technology, strengthening the Company’s

intellectual

property portfolio

Rutherford,

NJ, March 30, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),

a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes,

today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2025.

“In

2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology

and strengthening Glucotrack’s foundation. We strengthened our competitive position with three new patents issued by the USPTO

and continued to work closely with the FDA on alignment as we progress toward securing IDE approval and initiating our U.S. clinical

study program of our CBGM product,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We

entered 2026 with strong momentum and a reinforced balance sheet, positioning the Company to execute on important development and regulatory

milestones.”

Fourth

Quarter 2025 & Recent Highlights

Corporate

Highlights

● Completed

$4.0 million private placement.

○ In

December 2025, the Company entered into a securities purchase agreement with a single institutional

investor for the sale of 1,033,591 shares of common stock (or common stock equivalents in

lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at a combined

effective price of $3.87 per share and accompanying warrant, resulting in aggregate gross

proceeds of approximately $4.0 million before fees and expenses.

○ The

Company expects to use the net proceeds from the offering for working capital and general

corporate purposes.

● Strengthened

the Company’s intellectual property portfolio for novel implantable CBGM platform.

The three patents protect key technologies in Glucotrack’s CBGM system, a long-term

implantable device designed for three-year sensor longevity, including proprietary sensor

chemistry, intravascular lead design, and low-power electronics. Together, these innovations

bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices.

● Appointed

Usman Latif, MD, MBA, to the Company’s clinical advisory team. Dr. Latif is a prominent

pain management specialist and opinion leader with deep expertise in neuromodulation and

treatment of painful diabetic neuropathy (PDN). This expertise will be invaluable as the

Company advances its epidural glucose monitoring applications and integrates disease and

device management solutions for PDN patients.

● The

Company held its second Patient Advisory Board (PAB) meeting during which patients provided

feedback on the mobile application Glucotrack is developing to accompany its CBGM technology.

Advanced

Product and Clinical Development

● The

Company initiated a long-term, multicenter feasibility study in Australia to evaluate the

CBGM product performance and safety. The first phase of the clinical study provided early

product learnings about how the complexity of certain health conditions may impact study

eligibility as well as identified certain product improvements. Consequently, the Company is expediting discussions with the U.S. Food and Drug Administration (FDA) regarding our

planned U.S. clinical trial program that we expect to launch in the 2nd half of 2026, subject to FDA approval of our Investigational Device

Exemption (“IDE”) submission expected to be filed in Second Quarter 2026.

● Presented

at the 2025 Diabetes Technology Meeting held on October 28th, 2025 on the importance

of an integrated approach to diabetes management and highlighting how combining continuous

glucose monitoring with existing implantable technologies can enable one implant to address

multiple chronic conditions—redefining care for patients managing both diabetes and

other chronic conditions. The presentation showcased the company’s preclinical work

in epidural glucose monitoring which, when combined with spinal cord stimulation technologies,

has the potential to offer integrated device and disease management for patients living with

PDN.

Anticipated

Milestones

● Submitting

the Company’s IDE to the FDA in Second Quarter 2026 to initiate an initial human clinical Feasibility Study

of the CBGM product, subject to current agency response timelines.

● Presenting

clinical data demonstrating the safety and accuracy of the CBGM product at additional industry

conferences.

● Further

expanding Advisory Boards with world-renowned experts in endocrinology and cardiology and

others essential to the diabetes community.

● Continuing

to gain insight from patients living with diabetes on current management challenges and get

feedback on Glucotrack’s product development and commercialization strategies through

additional PAB meetings.

Financial

Results for the Year Ended December 31, 2025

Research

and Development Expenses: Research and development expenses were $9.8 million for the full year 2025 compared to $9.5 million for

the full year 2024. The increase of $0.3 million was primarily attributable to increased activities related to product design, development

and manufacturing activities and pre-clinical animal studies.

General

and Administrative Expenses: General and administrative expenses were $6.3 million for the full year 2025 compared to $5.1 million

for the full year 2024. The increase of $1.2 million was primarily attributable to increased professional fees, personnel costs and placement

agent fees.

Net

Loss: Net loss for the full year 2025 was $19.4 million compared to a net loss of $22.6 million for the full year 2024. The decrease

of $3.2 million was primarily attributable to non-cash losses of $7.5 million related to the settlement of debt and the issuance of warrants

containing derivative features recognized in the prior year.

Cash

Position: Cash and cash equivalents as of December 31, 2025, were $7.4 million, compared with $5.6 million in cash and cash equivalents

as of December 31, 2024. The net increase of $1.8 million in cash and cash equivalents compared to December 31, 2024 was attributable

to the $17.0 million from financing activities offset by cash used in operating and investing activities of $15.3 million.

Based

on current plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its 2026

operating plan by the end of Spring allowing for its IDE submission and initiate U.S. human clinical trials in 2026.

# #

About

Glucotrack, Inc.

Glucotrack,

Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The

Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack’s

Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor

longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and

is limited by federal (or United States) law to investigational use.

For

more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and

is not incorporated by reference into this press release.

Forward-Looking

Statements

This

news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements

contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting

the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan”

and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs

of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events

as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements,

whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements

made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated

by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us

or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and

could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that

may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance

its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating

to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct

of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain

qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings

with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended

December 31, 2025 as filed with the SEC on March 30, 2026.

Contacts:

Investor Relations:

Media:

investors@glucotrack.com

GlucotrackPR@icrinc.com

GLUCOTRACK

INC.

CONSOLIDATED

BALANCE SHEETS

thousands of US dollars

(except stock data)

December

31,

2025

December

31,

2024

Current

Assets

Cash

and cash equivalents

$ 7,383

$ 5,617

Other

current assets

284

151

Total

current assets

7,667

5,768

Operating

lease right-of-use asset, net

Property

and equipment, net

138

Restricted

cash

TOTAL

ASSETS

$ 7,838

$ 5,932

LIABILITIES

AND STOCKHOLDERS’ (DEFICIT) EQUITY

Current

Liabilities

Accounts

payable

$ 1,317

$ 992

Operating

lease liability, current

Promissory

notes

3,182

Convertible

promissory notes

Other

current liabilities

246

252

Total

current liabilities

4,773

1,275

Non-Current

Liabilities

Derivative

financial liabilities

17,421

Operating

lease liability, non-current

Loans

from stockholders

231

203

Total

liabilities

5,010

18,932

Commitments

and contingent liabilities

Stockholders’

(Deficit) Equity

Common

Stock of $0.001 par value (“Common Stock”):

250,000,000

shares authorized as of December 31, 2025 and 100,000,000 shares authorized as of December 31, 2024; 910,688 and 13,409 shares issued

and outstanding as of December 31, 2025 and 2024, respectively

Additional

paid-in capital

151,080

119,229

Receipts

on account of shares

3,544

228

Accumulated

other comprehensive income

(8 )

Accumulated

deficit

(151,838 )

(132,450 )

Total

stockholders’ (deficit) equity

2,828

(13,000 )

TOTAL

LIABILITIES AND STOCKHOLDERS’ (DEFICIT)

EQUITY

$ 7,838

$ 5,932

GLUCOTRACK

INC.

CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

thousands of US dollars

(except stock and per stock amounts)

2025

2024

Operating

expenses:

Research

and development expenses

$ 9,813

$ 9,499

General

and administrative expenses

6,277

5,048

Total

operating expenses

16,090

14,547

Loss

from operations

16,090

14,547

Other

income (expense):

Other

(income) expense

(26 )

(14 )

Change

in fair value of derivative liability

3,267

798

Loss

on equity issuance

1,925

Loss

on settlement of liabilities

4,758

Finance

expense, net

583

Total

other income

3,298

8,050

Net

loss

19,388

22,597

Other

comprehensive loss:

Foreign

currency translation adjustment

(49 )

(24 )

Comprehensive

loss

$ 19,339

$ 22,573

Basic

and diluted loss per share

$ 31.22

$ 4,106

Weighted

average number of Common Stock outstanding used in computing basic and diluted net loss per share

621,094

5,503

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (11227 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

Mar. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 30, 2026

Entity File Number

001-41141

Entity Registrant Name

GLUCOTRACK,

INC.

Entity Central Index Key

0001506983

Entity Tax Identification Number

98-0668934

Entity Incorporation, State or Country Code

Entity Address, Address Line One

301

Rte 17 North

Entity Address, Address Line Two

Ste. 800

Entity Address, City or Town

Rutherford

Entity Address, State or Province

Entity Address, Postal Zip Code

07070

City Area Code

(201)

Local Phone Number

842-7715

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

GCTK

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration